Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 168

Results For "platform"

1701 News Found

Meddo acquires Doxper in a cash and stock deal
Healthcare | August 03, 2021

Meddo acquires Doxper in a cash and stock deal

This deal makes Meddo, one of the largest health-tech players in India


Panacea Biotec gets license to produce Sputnik V vaccine at Baddi
News | July 05, 2021

Panacea Biotec gets license to produce Sputnik V vaccine at Baddi

The said batches have successfully passed all the checks for quality parameters both at the Gamaleya Center in Russia and at the Central Drug Laboratory, Kasauli in India


Triastek closes US $50 Mn Series B Financing
News | July 01, 2021

Triastek closes US $50 Mn Series B Financing

In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline


Zydus applies to the DCGI for EUA to launch ZyCoV-D
News | July 01, 2021

Zydus applies to the DCGI for EUA to launch ZyCoV-D

ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials


Glenmark receives ANDA approval for inhalation solution
News | June 24, 2021

Glenmark receives ANDA approval for inhalation solution

Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials will be manufactured in the company’s North American manufacturing facility based in Monroe, North Carolina


Cipla receives final approval for generic version of Brovana
News | June 24, 2021

Cipla receives final approval for generic version of Brovana

Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL is AN-rated generic therapeutic equivalent version of Sunovion Pharmaceuticals Inc.’s Brovana


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:


Bayer acquires Noria and PSMA Therapeutics
News | June 07, 2021

Bayer acquires Noria and PSMA Therapeutics

Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)


Lupin to foray into the digital healthcare space
Digitisation | June 03, 2021

Lupin to foray into the digital healthcare space

The company recently incorporated a new entity in the name of Lupin Digital Health Limited


Nanoform and Celanese explore ways to enhance drug delivery
News | May 25, 2021

Nanoform and Celanese explore ways to enhance drug delivery

Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.